Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines

Abstract

The invention relates to pyrrolo [1,2-a] thieno [3,2-f][1,4]diazepine compounds of the formula (I) ##STR1## in which: R.sub.1 is hydrogen; alkyl optionally substituted with alkoxy, hydroxy, cycloalkyl, or phenyl; or alkyl- or arylsulfonyl; R.sub.2 is hydrogen, phenyl, or phenylalkyl; alkyl optionally substituted with hydroxyl, alkoxy, oxo, cycloalkyl or phenyl; or optionally substituted amino; R.sub.3 represents hydrogen or alkyl, and R.sub.4 and R.sub.5 independently represent: hydrogen, alkyl optionally substituted with alkoxy, cycloalkyl, or phenyl; or phenyl; their isomers, diastereoisomers and enantiomers as well as their addition salts with pharmaceutically-acceptable acids. The compounds are useful for treating cerebral ischemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, and hyperglycemia and are obtained in a few steps from the corresponding substituted 2-(1-pyrrolyl)thiophenes ##STR2## Y=--CHO or H; X= CN, CONH.sub.2, CH.sub.2 NHCOR.sub.2, or CH.sub.2 NH.sub.2.

Description

The present invention relates to novel pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepines, to their process of preparation and to the pharmaceutical compositions containing them.

Some arylthienopyrrolodiazepines are already known for their action on the central nervous system (Japanese Patent 77 100-496).

A few 6-aryl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepines are also known, the synthesis of which has been published, without a pharmacological activity being described (S. Rault, Compte Rendus Hebd. des seances de l'Academie des sciences, series C, Vol. 285 No. 11 31 Oct. 1977 Paris pages 381-383).

The pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepines of the Applicant are products endowed with exceptional antihypoxic properties which are very advantageous in the treatment of cerebral aging and stroke.

The aging brain draws continually on its metabolic reserves to maintain its basal metabolism in a viable condition, any additional function demand resulting in an insufficiency of response. The compounds of the Applicant provide a solution to these problems by permitting an increase in the effective consumption of oxygen when there is increased metabolic demand without enhancing it excessively in the basal state. Their anti-hypermetabolic properties also make them valuable in the treatment of stroke.

The compounds of the Applicant are also extremely advantageous on account of their metabolic effects, since they possess substantial hypocholesterolemic, hypotriglyceridemic and hypoglycemic properties.

Finally, they possess, in greater or lesser degree according to the structure, antihypertensive, anxiolytic and PAF (Platelet Antagonist Factor)-antagonist properties.

More specifically, the invention relates to the pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepines of general formula (I): ##STR3## in which

R.sub.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with hydroxyl, alkoxy, cycloalkyl or aryl groups, an alkylsulfonyl group or an arylsulfonyl group optionally substituted on the aromatic ring with one or more lower alkyl groups or halogens,

R.sub.4 and R.sub.5 each represent, independently of one another, a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with hydroxyl, alkoxy, cycloalkyl or substituted or unsubstituted aryl groups, or an optionally substituted aryl or aralkyl group (the term substituted associated with the expressions aryl or aralkyl means that the aromatic rings may be substituted with one or more alkyl, nitro, alkoxy, trifluoromethyl or halogen groups),

R.sub.2 and R.sub.3 each represent, independently of one another, a hydrogen atom, an optionally substituted aryl or aralkyl group, a lower alkyl group having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with one or more hydroxyl, alkoxy, oxo, cycloalkyl or substituted or unsubstituted aryl groups, or a group --NR'R" for which R' and R" each represent, independently of one another, a hydrogen atom, a group --CO--R"' (R"' represents either an optionally substituted phenyl, or an indolyl, or an optionally substituted anilino group) or a lower alkyl group, or, together with the nitrogen atom to which they are attached, form a mono- or bicyclic heterocyclic system containing or otherwise another hetero atom and optionally substituted with a lower alkyl group or an optionally substituted aryl or aralkyl group (the term substituted for the expressions aryl, phenyl, anilino and aralkyl means that the aromatic rings may be substituted with one or more alkyl, nitro, alkoxy, trifluoromethyl or halogen groups),

with the proviso that, when R.sub.1 =R.sub.4 =R.sub.5 =H and one of the two substituents R.sub.2 or R.sub.3 is a hydrogen atom, then the other substituent can represent neither a hydrogen atom nor a methoxy group nor an optionally substituted aryl group,

their isomers, diastereoisomers and enantiomers,

their addition salts with a pharmaceutically acceptable inorganic or organic acid.

The invention also encompasses the processes for obtaining the compounds of general formula (I). The optimum processes for obtaining these compounds vary according to the nature of the substituents R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5, and are distinguished by the fact that:

either the starting material is a derivative of general formula (II): ##STR4## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted in a mixture of aqueous sodium hydroxide solution, ethanol and hydrogen peroxide with a methyl ketone of general formula (III): ##STR5## in which R.sub.6 is a cycloalkyl group or a lower alkyl group having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with alkoxy, cycloalkyl or aryl groups, so as to obtain the 5,6-dihydro-4-oxo-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of general formula (IV): ##STR6## in which R.sub.6 has the same meaning as in the general formula (III) and R.sub.4 and R.sub.5 the same meaning as in the compound of general formula (I), which is reduced in an aprotic medium with a mixed metal hydride so as to obtain the 5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of general formula (V): ##STR7## in which R.sub.4, R.sub.5 and R.sub.6 have the same meaning as in the formula (III), which may be treated in ethereal solution with gaseous hydrochloric acid to obtain the 5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride of general formula (VI): ##STR8## in which R.sub.4, R.sub.5 and R.sub.6 have the same meaning as in the formula (III),

or the starting material is the compound of general formula (VII): ##STR9## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted in suspension in water with a tertiary amine so as to obtain the compound of general formula (VIII): ##STR10## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reduced in an aprotic medium with a mixed metal hydride so as to obtain the compound of general formula (IX): ##STR11## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted in the presence of an amine with a halogenated derivative of general formula (X):

R.sub.1 Cl (X) in which R.sub.1 has the same meaning as in the compound of general formula (I), so as to obtain the compound of general formula (XI): ##STR12## in which R.sub.1, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I),

or the starting material is the compound of general formula (XII): ##STR13## in which R.sub.2, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is cyclized with phosphorus oxychloride so as to obtain the compound of general formula (XIII): ##STR14## in which R.sub.2, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reduced in an aprotic medium with a mixed metal hydride so as to obtain the 5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of general formula (XIV): ##STR15## in which R.sub.2, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which may be treated in ethereal solution with gaseous hydrochloric acid to obtain the 5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride of general formula (XV): ##STR16## in which R.sub.2, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I),

or the starting material is the compound of general formula (XVI): ##STR17## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted in alcohol under reflux with an aldehyde of general formula (XVII): ##STR18## in which R.sub.2 has the same meaning as in the compound of general formula (I), so as to obtain the compound of general formula (XVIII): ##STR19## in which R.sub.2, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is treated in ethereal solution with gaseous hydrochloric acid so as to obtain the 5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride of general formula (XV), in which R.sub.2, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I),

or the starting material is the compound of general formula (XIX): ##STR20## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted under reflux in alcohol and in the presence of concentrated hydrochloric acid with a ketone of general formula (XX): ##STR21## in which R.sub.2 and R.sub.3 have the same meaning as in the compound of general formula (I), so as to obtain the 5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride of general formula (XXI): ##STR22## in which R.sub.2, R.sub.3, R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I),

or the starting material is the compound of general formula (XIX), in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted in an alcoholic medium with ethyl 2-ethoxy-2-hydroxyacetate so as to obtain the compound of general formula (XXII): ##STR23## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reduced in alcoholic solution with a mixed metal hydride so as to obtain the 6-hydroxymethyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of general formula (XXIII): ##STR24## in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I),

or the starting material is the compound of general formula (VIII), in which R.sub.4 and R.sub.5 have the same meaning as in the compound of general formula (I), which is reacted under reflux of acetonitrile with an amine of general formula (XXIV):

HNR'R" (XXIV) in which R' and R" have the same meaning as in the compound of general formula (I), so as to obtain the compound of general formula (XXV): ##STR25## in which R.sub.4, R.sub.5, R' and R" have the same meaning as in the compound of general formula (I), which is reduced in an aprotic medium with a mixed metal hydrode so as to obtain the compound of general formula (XXVI): ##STR26## in which R.sub.4, R.sub.5, R' and R" have the same meaning as in the compound of general formula (I).

The compounds of general formula V, VI, IX, XI, XIV, XV, XXI, XXII, XXIII and XXVI form part of the invention and represent the compounds of general formula (I).

The pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepines of general formula (I), as well as their addition salts with a pharmaceutically acceptable inorganic or organic acid, are active principles possessing exceptional pharmacological and therapeutic properties.

These compounds possess strong antihypoxic properties which make them valuable in the treatment, inter alia, of cerebral aging, stroke and, more generally, ischemic syndromes of any localization. They are capable in mice of prolonging survival of the cerebral tissue during acute hypoxia.

These compounds also exhibit very advantageous metabolic properties, since they are strongly hypocholesterolemic, hypotriglyceridemic, hypolipidemic and hypoglycemic, leading to a very large number of potential therapeutic applications (obesity, atheroma, hyperlipidemia, hypercholesterolemia, etc.).

Finally, these compounds possess, and in greater or lesser degree according to their structure, antihypertensive, anxiolytic and PAF-antagonist properties.

The pyrrolo[1,2-]thieno[3,2-f][1,4]diazepines of general formula (I), as well as their addition salts with a pharmaceutically acceptable inorganic or organic acid such as, for example, hydrochloric, methanesulfonic, citric and maleic acids, may be made into pharmaceutical preparations according to generally known processes, such as, for example, into tablets, hard gelatin capsules, dragees, solutions for oral administration, injectable solutions, suspensions for oral administration, emulsions and suppositories.

Apart from inert, non-toxic and pharmaceutically acceptable excipients such as, for example, distilled water, glucose, lactose, starch, talc, vegetable oils, ethylene glycol, and the like, these preparations can also contain preservatives, stabilizers, wetting agents, emulsifiers, and the like.

The compositions thereby obtained are generally presented in the form of measured doses and can contain, depending on the conditions treated and the patient's age and sex, from 0.1 to 500 mg of active principle. They can, depending on the case, be administered orally, rectally or parenterally at dose of 0.1 to 500 mg from one to several times a day.

The examples which follow illustrate the invention and in no way limit the latter.

The characteristics of the .sup.1 H NMR spectrometry are collated in Tables I.

EXAMPLE 1

6-(2-Hydroxypentyl)-5,6-dihydro-4H, 5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Stage I: 6-(2-Oxo-1-pentyl)-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-]thieno[3,2-f][1,4]diazepine.

A solution of 12 g (0.059 mole) of 2-(2-formyl-1-pyrrolyl)-3-cyanothiophene in a mixture of 200 cm.sup.3 of 2-pentanone, 200 cm.sup.3 of ethanol, 200 cm.sup.3 of 5N sodium hydroxide and 15 cm.sup.3 of 33% hydrogen peroxide is heated to reflux for one hour. The ethanol and 2-pentanone are then removed under reduced pressure and the remainder of the reaction medium is poured into 200 cm.sup.3 of cold water. The precipitate formed is isolated by filtration, washed with water, dried and then recrystallized in an ether/acetone mixture.

11,5 g (68%) of 6-(2-oxo-1-pentyl)-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine are thereby obtained in the form of yellow crystals.

M.P. 186.degree. C. (ether/acetone)

Microanalysis: C.sub.15 H.sub.16 N.sub.2 O.sub.2 S M=288.36;

Calculated: C 62.49% H 5.59% N 9.72% S 11.10%;

Found: C 62.48% H 5.50% N 9.72% S 11.23%;

______________________________________IR spectrum (KBr) 3275 and 3170 cm.sup.-1 NH bands 3050, 2950, 2920, and CH bands 2870 cm.sup.-1 1705 cm.sup.-1 C.dbd.O (ketone) band 1640 cm.sup..sup.-1 C.dbd.O (lactam) band______________________________________

Stage II: 6-(2-Hydroxypentyl)-5,6-dihydro-4H, 5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

A solution of 2.6 g (0.009 mole) of 6-(2-oxo -1-pentyl)-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 550 cm.sup.3 of dichloromethane is added dropwise to a suspension of 1.50 g (0.04 mole) of lithium aluminum hydride in 20 cm.sup.3 of ethyl ether. The reaction mixture is stirred at room temperature for 30 minutes and then heated to reflux for 6 hours. After cooling, the solution obtained is cast on to 250 g of ice. The emulsion formed is filtered, the organic phase separated after settling has taken place and the aqueous phase extracted with 200 cm.sup.3 of methylene chloride. The organic phases are combined, dried over calcium chloride, purified on animal charcoal and then concentrated under reduced pressure. The residual oil is taken into solution in 300 cm.sup.3 of ethyl ether and the hydrochloride precipitated by bubbling gaseous hydrochloric acid through the solution. The precipitate obtained is filtered off, washed with ether and recrystallized in isopropanol.

1,4 g (50%) of 6-(2-hydroxypentyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride are thereby obtained in the form of gray crystals.

M.p. 214.degree. C. (isopropanol)

Microanalysis: C.sub.15 H.sub.21 N.sub.2 OSCl M=312.86;

Calculated: C 57.59% H 6.76% S 10.25% Cl 11.33%;

Found: C 57.80% H 7.09% S 9.59% Cl 10.69%;

______________________________________IR spectrum (KBr) 3350 cm.sup.-1 OH band 3310 cm.sup.-1 CH band 2960 to 2550 cm.sup.-1 NH.sub.2.sup.+ Cl.sup.- broad band 1565, 1430, 1330, main bands 1130, 1100, 960 and 735 cm.sup.-1______________________________________

EXAMPLE 2

6-(2-Cyclopropyl-2-hydroxyethyl)-5,6-dihydro -4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine chloride

Stage I: 6-(2-Cyclopropyl-2-oxoethyl)-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

Same working protocol as for Stage I of Example 1, starting with 6 g (0.029 mole) of 2-(2-formyl-1-pyrrolyl)-3-cyanothiophene and 50 cm.sup.3 of cyclopropyl methyl ketone.

4.80 g (57%) of 6-(2-cyclopropyl-2-oxoethyl)-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine are thereby obtained in the form of white crystals.

M.p. 200.degree. C. (ethyl ether/acetone)

Microanalysis: C.sub.15 H.sub.14 N.sub.2 O.sub.2 S M=286.35;

Calculated: C 62.91% H 4.92% N 9.78% S 11.19%;

Found: C 62.87% H 4.93% N 9.81% S 11.05%;

______________________________________IR spectrum (KBr) 3270 and 3180 cm.sup.-1 NH bands 3120, 3090, 3050 and 2890 cm.sup.-1 CH bands 1685 and 1640 cm.sup.-1 C.dbd.O bands______________________________________

Stage II: 6-(2-Cyclopropyl-2-hydroxyethyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 400 cm.sup.3 of dichloromethane and 0.7 g (0.017 mole) of lithium aluminum hydrode in 20 cm.sup.3 of ethyl ether.

0,7 g (54%) of 6-(2-cyclopropyl-2-hydroxyethyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride is thereby obtained in the form of white crystals.

M.p. 236.degree. C. (isopropanol)

Microanalysis: C.sub.15 H.sub.19 N.sub.2 OSCl M=310.84;

Calculated: C 57.96% H 6.16% N 0.01% Cl 11.41%;

Found: C 57.74% H 6.07% N 8.80% Cl 11.62%;

______________________________________IR spectrum (KBr) 3350 cm.sup.-1 OH band 3310, 2980 cm.sup.-1 CH band 2970 to 2540 cm.sup.-1 NH.sub.2.sup.+ Cl.sup.- broad band 1565, 1480, 1330, main bands. 1100, 1025, 960, 825, 760 and 735 cm.sup.-1______________________________________

EXAMPLE 3

6-(2-Hydroxy-3-methylbutyl)-5,6-dihydro -4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Stage I: 6-(3-Methyl-2-oxo-1-butyl) -5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

Same working protocol as for Stage I of Example 1, starting with 12 g (0.059 mole) of 2-(2-formyl -1-pyrrolyl)-3-cyanothiophene and 100 cm.sup.3 of isopropyl methyl ketone.

11.1 g (65%) of 6-(3-methyl-2-oxo-1-butyl)-5,6-dihydro-4-oxo-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine are thereby obtained in the form of yellow crystals.

M.p. 160.degree. C. (ethanol)

Microanalysis: C.sub.15 H.sub.16 N.sub.2 O.sub.2 S M=288.35;

Calculated: C 62.49% H 5.59% N 9.72% S 11.10%;

Found: C 62.50% H 5.80% N 9.69% S 11.07%;

______________________________________IR spectrum (KBr) 3280 and 3175 cm.sup.-1 NH bands 3060, 2960, 2930 and CH bands 2880 cm.sup.-1 1710 and 1650 cm.sup.-1 C.dbd.O bands______________________________________

Stage II: 6-(2-Hydroxy-3-methylbutyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

Same working protocol as for Stage II of Example 1, starting with 1.4 g (0.0049 mole) of 6-(3-methyl-2-oxobutyl)-5,6-dihydro-4-oxo -4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 400 cm.sup.3 of dichloromethane and 0.76 g (0.020 mole) of lithium aluminum hydride in 20 cm.sup.3 of ethyl ether.

0.8 g (52%) of 6-(2-hydroxy-3-methylbutyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride is thereby obtained in the form of a white powder.

M.p. 236.degree. C. (isopropanol)

Microanalysis: C.sub.15 H.sub.21 N.sub.2 OSCl M=312.86;

Calculated: C 57.96% H 6.76% S 10.25% Cl 11.33%;

found: C 57.50% H 6.88% S 9.67% Cl 11.02%;

______________________________________IR spectrum (KBr) 3380 cm.sup.-1 OH band 3110 cm.sup.-1 CH band 2960 to 2560 cm.sup.-1 NH.sub.2.sup.+ Cl.sup.- broad band 1570, 1480, 1330, main bands. 1260, 1090, and 715 cm.sup.-1______________________________________

EXAMPLE 4

6-(2-Phenyl-2-hydroxyethyl)-5,6-dihydro -4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Stage I: 6-Phenacyl-5,6-dihydro-4-oxo-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

Same working protocol as for Stage I of Example 1, starting with 1 g (0.0049 mole) of 2-(2-formyl-1-pyrrolyl)-3-cyanothiophene, 20 cm.sup.3 of acetophenone, 100 cm.sup.3 of 6N sodium hydroxide, 50 cm.sup.3 of ethanol and 5 cm.sup.3 of 33% hydrogen peroxide. After removal of the ethanol under reduced pressure, the reaction medium is poured into 100 cm.sup.3 of water. The oily precipitate which is composed of acetophenone and the oxodiazepine is extracted with ethyl ether. The ether phase is washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The acetophenone is removed by washing the residue with a petroleum ether/ethyl ether (50:50) mixture. The insoluble solid remaining is filtered off, dried and recrystallized in ethanol.

0.7 g (44%) of 6-phenacyl-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is thereby obtained in the form of white crystals.

M.p. 205.degree. C. (ethanol)

Microanalysis: C.sub.18 H.sub.14 N.sub.2 O.sub.2 S M=322.37;

Calculated: C 67.07% H 4.38% N 8.69% S 9.93%;

Found: C 66.83% H 4.63% N 8.80% S 9.68%.

______________________________________IR spectrum (KBr) 3320 and 3260 cm.sup.-1 NH bands 3090, 3060, and 2920 cm.sup.-1 CH bands 1675 and 1640 cm.sup.-1 C.dbd.O bands 1595, 1535, 1480, 1430, main bands. 1325, 1215, 775 and 685 cm.sup.-1______________________________________

Stage II: 6-(2-phenyl-2-hydroxyethyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

Same working protocol as for Stage II of Example 1, starting with 1.6 g (0.005 mole) of 6-phenacyl-5,6-dihydro-4-oxopyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 450 cm.sup.3 of dichloromethane and 0.76 g (0.02 mole) of lithium aluminum hydride in 20 cm.sup.3 of ethyl ether.

0.9 g (52%) of 6-(2-phenyl-2-hydroxyethyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride is thereby obtained in the form of white crystals.

M.p. 186.degree. C. (isopropanol)

Microanalysis: C.sub.18 H.sub.19 N.sub.2 OSCl M=346.87.

Calculated: C 62.33% H 5.52% S 9.24% Cl 10.22%.

Found: C 61.96% H 5.77% S 8.89% Cl 9.89%.

______________________________________IR spectrum (KBr) 3340 cm.sup.-1 OH bands 3110 cm.sup.-1 CH band 2970 to 2540 cm.sup.-1 NH.sub.2.sup.+ Cl.sup.- broad band 1565, 1330, 1100, main bands. 1070, 960 865, 735 and 705 cm.sup.-1______________________________________

EXAMPLE 5

6-(2-Hydroxypropyl)-5,6-dihydro-4H, 5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Stage I: 6-(2-Oxopropyl) and 5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

Same working protocol as for Stage I of Example 1, starting with acetone.

Stage II: 6-(2-Hydroxypropyl)-5,6-dihydro-4H, 5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

Same working protocol as for Stage II of Example 1, starting with 5 g (0.019 mole) of 6-(2-oxopropyl)-5,6-dihydro-4-oxo-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 500 cm.sup.3 of dichloromethane and 2.9 g (0.076 mole) of lithium aluminum hydride in 20 cm.sup.3 of ethyl ether.

2,2 g (41%) of 6-(2-hydroxypropyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride are thereby obtained in the form of beige crystals.

M.p. 226.degree. C. (isopropanol)

Microanalysis: C.sub.13 H.sub.17 N.sub.2 OSCl M=284.8.

Calculated: C 54.82% H 6.02% S 11.26% Cl 12.45%.

Found: C 54.98% H 6.04% S 11.09% Cl 12.67%.

______________________________________IR spectrum (KBr) 3390 cm.sup.-1 OH band 3110 cm.sup.-1 CH band 2960 to 2580 cm.sup.-1 NH.sub.2.sup.+ Cl.sup.- broad band 1570, 1480, 1330, main bands. 1180, 1100, 730 and 700 cm.sup.-1______________________________________

EXAMPLE 6

6-(2-Hydroxypropyl)-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine

A solution of 1 g (0.0035 mole) of 6-(2-hyroxypropyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride in 50 cm.sup.3 of water is alkalinized to pH 14 using sodium hydroxide pellets. The emulsion obtained is extracted with 3 times 50 cm.sup.3 of ethyl ether. The organic phases are separated after settling has taken place, combined, dried over magnesium sulfate and concentrated under reduced pressure until a crude product is obtained, which product is recrystallized in ethyl ether.

0.70 g (80%) of 6-(2-hydroxypropyl) -5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is thereby obtained in the form of white crystals.

M.p. 130.degree. C. (Et.sub.2 O)

Microanalysis: C.sub.13 H.sub.16 N.sub.2 OS M=248.34.

Calculated: C 62.87% H 6.49% N 11.28% S 12.91%.

Found: C 62.74% H 6.55% N 11.21% S 12.75%.

______________________________________IR spectrum (KBr) 3240 cm.sup.-1 NH band 3080, 2920, and CH bands 2830 cm.sup.-1 1580, 1480, 1310, 1135 and main bands 705 cm.sup.-1______________________________________

EXAMPLE 7

6-(2-Phenyl-2-hydroxyethyl)-5,6-dihydro -4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine

Same working protocol as for Example 6, starting with 1 g (0.0029 mole) of 6-(2-phenyl-2-hydroxyethyl)-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

0.72 g (80%) of 6-(2-phenyl-2-hydroxyethyl)-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is thereby obtained in the form of white crystals.

M.p. 190.degree. C. (Et.sub.2 O)

Microanalysis: C.sub.18 H.sub.16 N.sub.2 O.sub.2 S M=324.40.

Calculated: C 66.65% H 4.97% N 8.64% S 9.88%.

Found: C 66.56% H 4.89% N 8.52% S 9.68%.

______________________________________IR spectrum (KBr) 3300 cm.sup.-1 NH band 3100 and 2920 cm.sup.-1 CH bands 1580, 1480, 1330, 1095 and main bands 705 cm.sup.-1______________________________________

EXAMPLE 8

5-para-Tolylsulfonyl-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine

Stage I: 6-Hydroxy-5,6-dihydro-4-oxo-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

0.5 cm.sup.3 of triethylamine is added to a suspension of 2-(2-formyl-1-pyrrolyl)-3-carboxamidothiophene in 60 cm.sup.3 of water. The reaction medium is stirred for 12 hours at ambient temperature. The product gradually passes into solution and then reprecipitates. The precipitate obtained is isolated by filtration, washed with water, isolated and then recrystallized in water.

1.35 g (68% of 6-hydroxy-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine are thereby obtained in the form of beige crystals.

M.p. 166.degree. C.

Microanalysis: C.sub.16 H.sub.8 N.sub.2 O.sub.2 S M=220.45.

Calculated: C 54.53% H 3.66% N 12.71% S 14.56%.

Found: C 54.36% H 3.69% N 12.58% S 14.39%.

______________________________________IR spectrum (KBr) 3340 cm.sup.-1 OH band 3220 cm.sup.-1 NH band 3210 and 3110 cm.sup.-1 CH bands 1610 cm.sup.-1 C.dbd.O band 1500, 1450, 1320, 1205, 1005 main bands 830 and 720 cm.sup.-1______________________________________

Stage II: 5,6-Dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

A solution of 3 g (0.014 mole) of 6-hydroxy -5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 300 cm.sup.3 of dilchloromethane is added dropwise to a suspension of 2.08 g (0.055 mole) of lithium aluminum hydride in 15 cm.sup.3 of ethyl ether. The reaction medium is stirred for 30 minutes at room temperature and then heated to reflux for 6 hours.

After cooling, the solution obtained is cast on to 200 g of ice and the emulsion formed is drained. The organic phase is separated after settling has taken place and the aqueous phase extracted with 200 cm.sup.3 of dichloromethane. The organic phases are combined, dried over calcium chloride, purified on animal charcoal and concentrated under reduced pressure. 2.4 g (90%) of 5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine are thereby obtained in the form of an oil.

Stage III: 5-para-Tolylsulfonyl-5,5-dihydro -4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

An excess of para-toluenesulfonyl chloride is added to a solution of 1 g (0.0053 mole) of 5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 10 cm.sup.3 of pyridine, and the reaction mixture is then stirred at room temperature for one hour. The pyridine is removed by distillation under reduced pressure and the oily residue ground in 100 cm.sup.3 of water. The emulsion formed is extracted with 3 times 100 cm.sup.3 of ethyl ether.

The organic phases are separated after settling has taken place, combined, washed with acidulated water, dried over magnesium sulfate and finally concentrated under reduced pressure.

The solid obtained is then recrystallized in ethyl ether.

0.5 g (27%) of 5-para-tolylsulfonyl-5,6-dihydro-4-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is thereby obtained in the form of beige crystals.

M.p. 173.degree. C. (ethyl ether)

Microanalysis: C.sub.17 H.sub.16 N.sub.2 O.sub.2 S M=344.44.

Calculated: C 59.28% H 4.68% N 8.13% S 18.68%.

Found: C 59.15% H 4.74% N 8.06% S 19.40%.

______________________________________IR spectrum (KBr) 3100, 2960, 2820 cm.sup.-1 CH bands 1580, 1485, 1350, 1330, 1155, main bands 1080, 905, 805, 710 and 655 cm.sup.-1______________________________________

EXAMPLE 9

6,6-Dimethyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

A solution of 2 g (0.0093 mole) of 2-(1-pyrrolyl)-3-(aminomethyl)thiophene hydrochloride in a mixture of 10 cm.sup.3 of acetone, 50 cm.sup.3 of methanol and 5 cm.sup.3 of concentrated hydrochloric acid is heated to reflux for 3 hours. After cooling, the precipitate formed by the addition of petroleum ether is isolated by filtration, washed with ethyl ether and recrystallized in isopropanol.

1.5 g (59%) of 6,6-dimethyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride are thereby obtained.

M.P. 250.degree. C. (isopropanol)

Microanalysis: C.sub.12 H.sub.15 N.sub.2 SCl M=254.76.

Calculated: C 56.57% H 5.93% Cl 13.91% N 10.94%.

Found: C 56.53% H 6.07% Cl 13.70% N 10.94%.

______________________________________IR spectrum (KBr) 2910, 2660 and 2620 cm.sup.-1 NH.sub.2.sup.+ bands 1575, 1560, 1480, 1440, 1340, main bands 980, 875 and 745 cm.sup.-1______________________________________

EXAMPLE 10

6-Hydroxymethyl-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine

0.60 g (0.015 mole) of sodium borohydride is added to a solution of 2 g (0.007 mole) of 6-ethoxycarbonyl -5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 30 cm.sup.3 of methanol. The reaction medium is brought to reflux for 2 hours and the methanol is then removed under reduced pressure. The residue is taken up with 100 cm.sup.3 of water and the aqueous solution is extracted with ethyl acetate.

The organic phases are decolorized over animal charcoal, dried over magnesium sulfate and concentrated under reduced pressure.

The white precipitate obtained is recrystallized in ethyl ether.

1 g (60%) of 6-hydroxymethyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is thereby obtained in the form of white crystals.

M.p. 166.degree. C. (ethyl ether)

Microanalysis: C.sub.11 H.sub.12 N.sub.2 OS M=220.28.

Calculated: C 59.98% H 5.49% N 12.72% S 14.55%.

Found: C 60.04% H 5.58% N 12.61% S 14.38%.

______________________________________IR spectrum (KBr) 3430 cm.sup.-1 OH band 3260 cm.sup.-1 NH band 1580, 1480, 1400, 1340, 1320, main bands 1160, 1040, 840 and 720 cm.sup.-1______________________________________

6-Ethoxycarbonyl-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is obtained by condensation of 2-(1-pyrrolyl)-3-(aminomethyl)thiophene with ethyl 2-ethoxy-2-hydroxyacetate in an ethanolic medium.

EXAMPLE 11

6-Cyclopropyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

A solution of 2 g (0.008 mole) of 6-cyclopropyl -4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine in 50 cm.sup.3 of anhydrous ethyl ether is added dropwise to a suspension of 0.30 g (0.008 mole) of lithium aluminum hydride in 50 cm.sup.3 of anhydrous ethyl ether. The reaction medium is brought to reflux for 4 hours, then cooled and poured slowly into 100 cm.sup.3 of water.

The ether phase is separated after settling has taken place, washed with water, dried over magnesium sulfate and concentrated under reduced pressure. 6-Cyclopropyl -5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is thereby obtained in the form of an oil.

This oil is taken up in 50 cm.sup.3 of ethyl ether and a stream of gaseous hydrochloric acid is bubbled through for 1 minute. The precipitate is isolated by filtration, washed with ethyl ether and then recrystallized in isopropanol.

6-Cyclopropyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride is thereby obtained in a 90% yield.

M.p. 250.degree. C. (isopropanol

Microanalysis: C.sub.13 H.sub.15 N.sub.2 SCl M=266.78.

Calculated C 58.92% H 5.67%.

Found: C 57.94% H 5.62%.

______________________________________IR spectrum (KBr) 2920, 2780 and 2560 cm.sup.-1 NH.sub.2.sup.+ bands 3120 cm.sup.-1 CH band 1570, 1480, 1440, 1340, 1140, main bands 1100, 900 and 880 cm.sup.-1______________________________________

6-cyclopropyl-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is obtained by condensation of cyclopropanecarboxylic acid chloride with 2-(1-pyrrolyl)-3-(aminomethyl) thiophene in pyridine, followed by a cyclization of the amide formed by means of POCL.sub.3.

EXAMPLE 12

6-Methyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Same working protocol as for Example 11, starting with 6-methyl-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine. The 6-Methyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine obtained is purified by distillation under vacuum. The corresponding hydrochloride is prepared in the same manner as in Example 11.

6-Methyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride is thereby obtained in a 90% yield.

M.p. 242.degree. C. (isopropanol)

Microanalysis: C.sub.11 H.sub.13 N.sub.2 SCl M=240.75.

Calculated: C 54.88% H 5.44% Cl 14.73% S 13.32%.

Found: C 55.54% H 5.64% Cl 14.08% S 12.83.

______________________________________IR spectrum (KBr) 2920, 2600 cm.sup.-1 NH.sub.2.sup.+ bands 1570, 1550, 1480, 1440, 1390, main bands 1330, 1260, 1180, 1100, 1030 and 970 cm.sup.-1______________________________________

6-Methyl-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is obtained by acylation of 2-(2-pyrrolyl)-3-(aminomethyl)thiophene in a mixture of acetic acid and acetic anhydride, followed by a cyclization of the amide formed by means of phosphorus oxychloride.

EXAMPLE 13

6-Ethyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Same working protocol as for Example 11, starting with 6-ethyl-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine. 6-Ethyl-5,6-dihydro-4H, 5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride is thereby obtained in a 95% yield.

M.p. 194.degree. C. (isopropanol)

Microanalysis: C.sub.12 H.sub.15 N.sub.2 SCl M=254.77.

Calculated: C 56.57% H 5.93S 12.58%.

Found: C 56.81% H 5.85% S 12.69%.

______________________________________IR spectrum (KBr) 2920, 2740, 2540 cm.sup.-1 NH.sub.2.sup.+ bands 1570, 1480, 1380, 1260, 1170, main bands 1100, 900 and 860 cm.sup.-1______________________________________

6-Ethyl-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine is obtained by acylation of 2(1-pyrrolyl)-3-(aminomethyl)thiophene in pyridine with propionyl chloride, followed by a cyclization of the amide formed by means of phosphorus oxychloride.

EXAMPLE 14

2,3-Dimethyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride

Stage I: 4,5-Dimethyl-2-(1-pyrrolyl)-3-cyanothiophene.

A solution of 2 g (0.0145 mole) of 2-amino-3-cyano-4,5-dimethylthiophene and 2 cm.sup.3 (0.0160 mole) of 2,5-dimethoxytetrahydrofuran in 25 cm.sup.3 of acetic acid is heated to reflux for 30 minutes. The acetic acid is removed under vacuum and the residual brown oil distilled.

2 g (68%) of 4,5-dimethyl-2-(1-pyrrolyl)-3-cyanothiophene are thereby obtained in the form of white crystals.

M.p. 45.degree. C.

Microanalysis: C.sub.11 H.sub.10 N.sub.2 S M=344.44.

Calculated: C 65.32% H 4.98% N 13.85% S 15.85%.

Found: C 65.15% H 5.08% N 13.63% S 15.63%.

______________________________________IR spectrum (KBr) 3170 and 2920 cm.sup.-1 CH bands 2220 cm.sup.-1 CN band 1520, 1425, 1090, 915 and main bands 720 cm.sup.-1______________________________________

Stage II: 4,5-Dimethyl-2-(2-formyl-1-pyrrolyl)-3-cyanothiophene.

13 g (0.064 mole) of 4,5-dimethyl-2-(1-pyrrolyl)-3-cyanothiophene, dissolved in 20 cm.sup.3 of DMF, are added at room temperature and in a single portion to a complex, prepared beforehand at 0.degree. C., of 7.4 cm.sup.3 (0.096 mole) of DMF and 8.8 cm.sup.3 (0.096 mole) of phosphorus oxychloride. The reaction and then 1 hour at 100.degree. C. After cooling, the reaction medium is poured on to 300 g of ice, stirred for 20 minutes and then alkanized with 6N sodium hydroxide solution. The precipitate formed is isolated by filtration, washed with water, dried and then recrystallized in ethyl ether.

13.7 g (93%) of 4,5-dimethyl-2-(2-formyl-1-pyrrolyl)-3-cyanothiophene are thereby obtained in the form of white crystals.

M.p. 154.degree. C. (ethyl ether)

Microanalysis: C.sub.12 H.sub.10 N.sub.2 OS M=230.25.

Calculated: C 62.61% H 4.34% N 12.17% S 13.9%.

Found: C 62.74% H 4.49% N 12.09% S 14.04%.

______________________________________IR spectrum (KBr) 3030, 2840 and 2750 cm.sup.-1 CH bands 2220 cm.sup.-1 CN band______________________________________

Stage III: 4,5-Dimethyl-2-(2-formyl-1-pyrrolyl)-3-thiophenecarboxylic acid.

A solution of 5 g (0.022 mole) of 4,5-dimethyl -2-(2-formyl-1-pyrrolyl)-3-cyanothiophene in 100 cm.sup.3 of 6N sodium hydroxide and 120 cm.sup.3 of ethanol is heated to reflux for 6 hours. The ethanol is removed under reduced pressure and the aqueous solution diluted with 200 cm.sup.3 of water and acidified with 2N hydrochloric acid solution. The precipitate formed is isolated by filtration, washed with water, dried and recrystallized.

3.5 g (64%) of 4,5-dimethyl-2-(2-formyl-1-pyrrolyl)-3-thiophenecarboxylic acid are thereby obtained.

Stage IV: 4,5-Dimethyl-2-(2-formyl-1-pyrrolyl)-3-carboxamidothiophene.

1.2 cm.sup.3 (0.008 mole) of triethylamine are added at 0.degree. C. to a suspension of 2 g (0.008 mole) of 4,5-dimethyl-2-(2-formyl-1-pyrrolyl)-3-thiophenecarboxylic acid in 200 cm.sup.3 of ethyl ether. After stirring for 20 minutes, 0.8 cm.sup.3 (0.008 mole) of ethyl chloroformate is added to the suspension maintained at 0.degree. C. The reaction mixture is stirred for 20 minutes and the precipitate of triethylammonium chloride formed is then removed by filtration. Ammonia is bubbled into the solution maintained at 0.degree. C., and the precipitate which forms instantaneously is isolated by filtration. The precipitate is washed with ether, dried and recrystallized.

1.19 g (60%) of 4,5-dimethyl-2-(2-formyl-1-pyrrolyl)-3-carboxamidothiophene are thereby obtained.

Stage V: 2,3-Dimethyl-6-hydroxy-4-oxo-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

2 g (0.008 mole) of 4,5-dimethyl-2-(2-formyl-1-pyrrolyl)-3-carboxamidothiophene are suspended in 20 cm.sup.3 of water and then stirred at room temperature. The precipitate obtained is isolated by filtration, washed with water, dried and then recrystallized.

1.29 g (65%) of 2,3-dimethyl-6-hydroxy-5,6-dihydro-4-oxo-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine are thereby obtained.

Stage VI: 2,3-Dimethyl-5,6-dihydro-4H, 5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

Same working protocol as for Stage II of Example 8, starting with 5 g (0.02 mole) of 2,3-dimethyl-6-hydroxy-4-oxo-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine.

The oil obtained is taken up in 300 cm.sup.3 of ethyl ether and a stream of gaseous hydrochloric acid is then bubbled through the mixture. The precipitate obtained is isolated by filtration, washed with ethyl ether and then recrystallized.

2.60 g (51%) of 2,3-dimethyl-5,6-dihydro -4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride are thereby obtained.

M.p. above 260.degree. C.

TABLE Ia__________________________________________________________________________(The chemical shifts are in ppm) ##STR27## NH.sub.2.sup..sym. CH.sub.2Ex R H.sub.2 H.sub.3 H.sub.7 H.sub.8 H.sub.9 5 4 H.sub.6 Other protons__________________________________________________________________________1 CH.sub.2 CH.sub.2 CH.sub.3 7.45 7.12 6.44 6.36 7.26 9.97 4.16 4.21 ##STR28## ##STR29## 7.46 7.13 6.43 6.35 7.27 9.93 4.17 4.25 ##STR30##3 ##STR31## 7.41 7.06 6.40 6.33 7.23 9.77 4.18 4.26 ##STR32##4 C.sub.6 H.sub.5 7.48 7.14 6.61 6.41 7.30 9.86 4.28 4.54 ##STR33##5 CH.sub.3 7.45 7.12 6.49 6.35 7.27 10 3.96 4.25 ##STR34##__________________________________________________________________________ TABLE Ib__________________________________________________________________________(The chemical shifts are in ppm) ##STR35## NH CH.sub.2Ex R H.sub.2 H.sub.3 H.sub.7 H.sub.8 H.sub.9 5 H.sub.6 4 Other protons__________________________________________________________________________6 CH.sub.3 6.90 6.70 6.06 6.19 7.00 6.95 4.11 4.24 CH 4.02 CH.sub.3 1.25 CH.sub.2 1.87-2.047 C.sub.6 H.sub.5 6.91 6.62 6.06 6.15 6.96 6.95 4.35 4.33 CH 3.74 CH.sub.2 2.49 C.sub.6 H.sub.5 7.37__________________________________________________________________________ TABLE Ic______________________________________(The chemical shifts are in ppm) ##STR36## CH.sub.2 CH.sub.2Ex H.sub.3 H.sub.7 H.sub.8 H.sub.9 4 6 Other protons______________________________________8 6.87 6.16 6.12 6.87 4.42 3.37 CH.sub.3 2.33 C.sub.6 H.sub.4 7.52 and 7.26______________________________________ TABLE Id__________________________________________________________________________(The chemical shifts are in ppm) ##STR37## CH.sub.2Ex R R.sub.1 H.sub.2 H.sub.3 H.sub.7 H.sub.8 H.sub.9 4 Other protons__________________________________________________________________________ 9 CH.sub.3 CH.sub.3 7.30 6.93 6.20 6.30 7.10 4.1 ##STR38##11 H ##STR39## 7.38 7.06 6.35 6.60 7.23 4.25 3.70 ##STR40##12 H CH.sub.3 7.42 7.10 6.34 6.44 7.25 4.28 3.63 ##STR41##13 H C.sub.2 H.sub.5 7.41 7.09 6.34 6.44 7.24 4.22 3.61 ##STR42##__________________________________________________________________________ TABLE Ie______________________________________(The chemical shifts are in ppm) ##STR43## OtherEx R R.sub.1 H.sub.2 H.sub.3 H.sub.7 H.sub.8 H.sub.9 CH.sub.2 protons______________________________________10 H CH.sub.2 OH 7.12 6.78 6.04 6.11 7.014.00 CH.sub.2 3.65 OH4.71 H.sub.6 3.8______________________________________ TABLE If______________________________________(The chemical shifts are in ppm) ##STR44##Ex H.sub.7 H.sub.8 H.sub.9 Other protons______________________________________14 6.39 6.27 7.18 CH.sub.2 : 3.95 (s) CH.sub.2 : 4.10 (s) CH.sub.3 : 2.06 (s) CH.sub.2 : 2.25 (s) NH.sub.2.sup..sym. : 10.05______________________________________

EXAMPLE 15

Tablet containing 3 mg of 2,3-dimethyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinium chloride.

______________________________________2,3-Dimethyl-5,6-dihydro-4H,5H.sup.+ -pyrrolo[1,2-a]- 3 gthieno[3,2-f][1,4]diazepinium chlorideWheat starch 110 gCornstarch 85 gMagnesium stearate 15 gTalc 20 g______________________________________ per 1000 tablets containing 3 mg of active principle.

EXAMPLE 16

Pharmacological Study

Demonstration of the antihypoxic properties

a) Principle

During aging, the fall in intrinsic cerebral reserves results in an inability to respond to any fresh metabolic demand.

During stroke, selective neuronal vulnerability appears in the cells which have the greatest metabolic demand.

The common point between these pathologies is the deficit in oxygen utilisation which, more often than not, leads the metabolism to veer towards the anaerobic state.

Stresses of this kind may be reproduced experimentally and acutely by hypoxia in order to investigate novel cerebroprotective compounds.

In effect, the analogy between hypoxia and the cerebral disorders linked to aging or to circulatory insufficiency are expressed, in particular, by:

a fall in the energy reserves,

a lower resistance to stress,

a fall in the oxygen-dependent synthesis of neurotransmitters,

a drop in mnestic capacity.

The compounds of the present invention were hence tested for their capacity to prolong survival of the cerebral tissue in mice.

b) Methodology

Male CDl mice (Charles River) are subjected to an acute hypoxia of the hypobaric type 30 minutes after receiving the test compound intraperitoneally. For this purpose, they are placed in a chamber in which the barometric pressure may be lowered rapidly to a value of 160 mbar.

The renewal of air effected during the test makes it possible to produce a hypoxia and not an asphyxia or an anoxia which could require a protection of vascular origin.

Brain death is obtained in approximately 15 seconds after production of the hypoxic pressure.

The mean survival time of a treated batch is compared with that of a control batch receiving only the injection solvent.

c) Results

The compounds of the invention do not bring about a neuro-behavioral effect of the sedation type, in contrast to diazepam. They significantly counteract cerebral hypoxia.

Acute hypoxia: Percentage increase in cerebral survival time.

______________________________________ mg/kg IPExample 3 10 30 100______________________________________2 +12 +17 +22 +943 +9 +11 +19 +825 +11 +15 +27 +12514 +35 +54 +128 +250______________________________________

Claims

1. A pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine selected from those of the formula (I): ##STR45## in which R.sub.1 represents hydrogen, lower alkyl having 1 to 6 carbon atoms, inclusive, branched or otherwise, optionally substituted with hydroxyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkyl or phenyl; C.sub.1 -C.sub.3 alkylsulfonyl or phenylsulfonyl optionally substituted on the aromatic ring with one or more C.sub.1 -C.sub.3 lower alkyl or halogen,

R.sub.4 and R.sub.5 each represent, independently of one another, hydrogen, lower alkyl having 1 to 6 carbon atoms, inclusive, branched or otherwise, optionally substituted with hydroxyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkyl or substituted or unsubstituted phenyl, or phenyl or phenyl C.sub.1 -C.sub.3 -alkyl optionally substituted with one or more C.sub.1 -C.sub.3 alkyl, nitro, C.sub.1 -C.sub.3 alkoxy, trifluoromethyl or halogen,

R.sub.2 represents hydrogen, optionally substituted phenyl or phenyl C.sub.1 -C.sub.3 -alkyl, lower alkyl having 1 to 6 carbon atoms, inclusive, branched or otherwise, optionally substituted with one or more hydroxyl, C.sub.1 -C.sub.6 alkoxy, oxo, C.sub.3 -C.sub.7 cycloalkyl or substituted or unsubstituted phenyl, or a group --NR'R" in which R' and R" each represent, independently of one another, hydrogen, --CO--R"'

wherein R"' represents an optionally-substituted phenyl, or an indolyl, or an optionally-substituted anili-1- or -2-yl group, or a C.sub.1 -C.sub.6 lower alkyl group or, together with the nitrogen atom to which they are attached, R' and R" form a monocyclic heterocyclic system optionally-substituted with C.sub.1 -C.sub.6 lower alkyl or an optionally-substituted phenyl or phenyl C.sub.1 -C.sub.3 -alkoxy group,

the term "substituted" associated with the expressions phenyl, anili-1- or -2-yl, and phenyl C.sub.1 -C.sub.3 -alkyl, where not otherwise specified, meaning that the aromatic rings may be substituted with one or more C.sub.1 -C.sub.3 alkyl, nitro, C.sub.1 -C.sub.3 alkoxy, trifluoromethyl or halogen groups or atoms,

and R.sub.3 =hydrogen or C.sub.1 -C.sub.3 alkyl;

with the proviso that, when three of R.sub.1, R.sub.4, and R.sub.5 are H or unsubstituted alkyl, then R.sub.2 can represent neither a hydrogen atom, a methyl (when R.sub.3 equals H), a phenyl, or substituted phenyl group,

its isomers, diastereoisomers and enantiomers, and

its addition salts with a pharmaceutically-acceptable inorganic or organic acid.

2. A compound as claimed in claim 1 for which R.sub.4 and R.sub.5 represent either a hydrogen atom or a lower alkyl group having 1 to 6 carbon atoms, as well as its isomers and their addition salts with a pharmaceutically-acceptable acid.

3. A compound as claimed in claim 1 which is selected from 6-(2-hydroxypentyl)-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR46##

4. A compound as claimed in claim 1 which is selected from 6-(2-cyclopropyl-2-hydroxyethyl)-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers and their addition salts with a pharmaceutically-acceptable acid ##STR47##

5. A compound as claimed in claim 1 which is selected from 6-(2-hydroxy-3-methylbutyl)-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR48##

6. A compound as claimed in claim 1 which is selected from 6-(2-phenyl-2-hydroxyethyl)-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR49##

7. A compound as claimed in claim 1 which is selected from 6-(2-hydroxypropyl)-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR50##

8. A compound as claimed in claim 1 which is 5-para-tolysulfonyl-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula ##STR51##

9. A compound as claimed in claim 1 which is 6,6-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its addition salts with a pharmaceutically-acceptable acid ##STR52##

10. A compound as claimed in claim 1 which is selected from 6-(hydroxymethyl)-5,6-dihydro-4H -pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR53##

11. A compound as claimed in claim 1 which is selected from 6-cyclopropyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR54##

12. A method as claimed in claim 1 wherein the compound is selected from 6-methyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR55##

13. A compound as claimed in claim 1 which is selected from 6-ethyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula, as well as its isomers, and their addition salts with a pharmaceutically-acceptable acid ##STR56##

14. A compound which is selected from the group consisting of 2,3-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine of the following formula and its addition salts with a pharmaceutically-acceptable acid ##STR57##

15. A pharmaceutical composition useful for combating ischemia or cerebral hypoxia, aging and a metabolic disease selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, and hyperglycemia, containing as active principle an effective amount of a compound which is a pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine selected from those of the formula (I): ##STR58## in which R.sub.1 represents hydrogen, lower alkyl having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with hydroxyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkyl or phenyl; C.sub.1 -C.sub.3 alkylsulfonyl or phenylsulfonyl optionally substituted on the aromatic ring with one or more C.sub.1 -C.sub.3 lower alkyl or halogen,

R.sub.4 and R.sub.5 each represent, independently of one another, hydrogen, lower alkyl having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with hydroxyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkyl or substituted or unsubstituted phenyl, or phenyl or phenyl C.sub.1 -C.sub.3 -alkyl optionally substituted with one or more C.sub.1 -C.sub.3 alkyl, nitro, C.sub.1 -C.sub.3 alkoxy, trifluoromethyl or halogen,

R.sub.2 represents hydrogen, optionally substituted phenyl or phenyl C.sub.1 -C.sub.3 -alkyl, lower alkyl having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with one or more hydroxyl, C.sub.1 -C.sub.6 alkoxy, oxo, C.sub.3 -C.sub.7 cycloalkyl or substituted or unsubstituted phenyl, or a group --NR'R" in which R' and R" each represent, independently of one another, hydrogen, --CO--R"' wherein R"' represents an optionally-substituted phenyl, or an indolyl, or an optionally-substituted anili-1- or -2-yl group, or a C.sub.1 -C.sub.6 lower alkyl group or, together with the nitrogen atom to which they are attached, R' and R" form a monocyclic heterocyclic system optionally-substituted with C.sub.1 -C.sub.6 lower alkyl or an optionally-substituted phenyl or phenyl C.sub.1 -C.sub.3 -alkoxy group,

the term "substituted" associated with the expressions phenyl, anili-1- or -2-yl, and phenyl C.sub.1 -C.sub.3 -alkyl, where not otherwise specified, meaning that the aromatic rings may be substituted with one or more C.sub.1 -C.sub.3 alkyl, nitro, C.sub.1 -C.sub.3 alkoxy, trifluoromethyl or halogen groups or atoms,

and R.sub.3 =hydrogen or C.sub.1 -C.sub.3 alkyl;

with the proviso that, when R.sub.1 =R.sub.4 =R.sub.5 =H and one of the two substituents R.sub.2 or R.sub.3 is a hydrogen atom, the other substituent can represent neither a hydrogen atom or an optionally-substituted aryl group,

its isomers, diastereoisomers and enantiomers, and

its addition salts with a pharmaceutically-acceptable inorganic or organic acid,

in combination with a pharmaceutically-acceptable excipient or vehicle.

16. A method for treating a living mammal afflicted with ischemia or cerebral hypoxia, comprising the step of administering to the said living animal an amount of a compound which is a pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepine selected from those of the formula (I): ##STR59## in which R.sub.1 represents hydrogen, lower alkyl having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with hydroxyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkyl or phenyl; C.sub.1 -C.sub.3 alkylsulfonyl or phenylsulfonyl optionally substituted on the aromatic ring with one or more C.sub.1 -C.sub.3 lower alkyl or halogen,

R.sub.4 and R.sub.5 each represent, independently of one another, hydrogen, lower alkyl having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with hydroxyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkyl or substituted or unsubstituted phenyl, or phenyl or phenyl C.sub.1 -C.sub.3 -alkyl optionally substituted with one or more C.sub.1 -C.sub.3 alkyl, nitro, C.sub.1 -C.sub.3 alkoxy, trifluoromethyl or halogen,

R.sub.2 represents hydrogen, optionally substituted phenyl or phenyl C.sub.1 -C.sub.3 -alkyl, lower alkyl having 1 to 6 carbon atoms, branched or otherwise, optionally substituted with one or more hydroxyl, C.sub.1 -C.sub.6 alkoxy, oxo, C.sub.3 -C.sub.7 cycloalkyl or substituted or unsubstituted phenyl, or a group --NR'R" in which R' and R" each represent, independently of one another, hydrogen, --CO--R"' wherein R"' represents an optionally-substituted phenyl, or an indolyl, or an optionally-substituted anili-1- or -2-yl group, or a C.sub.1 -C.sub.6 lower alkyl group or, together with the nitrogen atom to which they are attached, R' and R" form a monocyclic heterocyclic system optionally-substituted with C.sub.1 -C.sub.6 lower alkyl or an optionally-substituted phenyl or phenyl C.sub.1 -C.sub.3 -alkoxy group,

the term "substituted" associated with the expressions phenyl, anili-1- or -2-yl, and phenyl C.sub.1 -C.sub.3 -alkyl, where not otherwise specified, meaning that the aromatic rings may be substituted with one or more C.sub.1 -C.sub.3 alkyl, nitro, C.sub.1 -C.sub.3 alkoxy, trifluoromethyl or halogen groups or atoms,

and R.sub.3 =hydrogen or C.sub.1 -C.sub.3 alkyl;

with the proviso that, when R.sub.1 =R.sub.4 =R.sub.5 =H and one of the two substituents R.sub.2 or R.sub.3 is a hydrogen atom, the other substituent can represent neither a hydrogen atom or an optionally-substituted aryl group,

its isomers, diastereoisomers and enantiomers, and

its addition salts with a pharmaceutically-acceptable inorganic or organic acid,

which is effective for alleviation of the said condition.